• Explore /
  • Poster
  • / Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).

Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).

Abstract Video & Slides Poster

Authors

null

Kyriakos P. Papadopoulos

START-San Antonio, San Antonio, TX

Kyriakos P. Papadopoulos , Nehal J. Lakhani , Timothy A. Yap , Allison L Naumovski , Karen S Brown , Ben Umiker , Lara McGrath , Weidong Zhang , Edward Stack , Gosia Riley , Nancy Mota , Christina Tasillo , Haley Laken , Elizabeth G. Trehu , Johan Baeck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04669899

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2672)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2672

Abstract #

TPS2672

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Iwona A. Lugowska

First Author: Jiaxin Niu

First Author: Susanna Varkey Ulahannan